Associated Chromosome Trap for Identifying Long-range DNA Interactions

Summary

The associated chromosome trap (ACT) assay is a novel unbiased method for identifying long-range DNA interactions. The characterization of long range DNA interactions will allow us to determine the relationship of nuclear architecture to gene expression in both normal physiology and in diseased states.

Abstract

Genetic information encoded by DNA is organized in a complex and highly regulated chromatin structure. Each chromosome occupies a specific territory, that may change according to stage of development or cell cycle. Gene expression can occur in specialized transcriptional factories where chromatin segments may loop out from various chromosome territories, leading to co-localization of DNA segments which may exist on different chromosomes or far apart on the same chromosome. The Associated Chromosome Trap (ACT) assay provides an effective methodology to identify these long-range DNA associations in an unbiased fashion by extending and modifying the chromosome conformation capture technique. The ACT assay makes it possible for us to investigate mechanisms of transcriptional regulation in trans, and can help explain the relationship of nuclear architecture to gene expression in normal physiology and during disease states.

Protocol

1. Formaldehyde fixation of long-range chromatin interactions

1. Culture human cell line HL-60 in RPMI1640 medium with 15% FBS and 1 x penicillin/streptomycin to 80-90% confluence in an incubator supplied with 5% CO₂ at 37°C.
2. Collect the cells into a 50-ml Nunc tube, centrifuge at 1,200 rpm for 15 minutes, and then remove the medium by aspiration
3. Add 5 ml of culture medium to resuspend the cell pellets, and count the cells using a hemocytometer. Take approximately 1 x 10⁷ cells to a volume of 40 ml with RPMI1640 /10% FBS, then add 1.7 ml of 37% formaldehyde to fix the dilute chromatin.
4. Incubate at room temperature for 10 minutes with gentle shaking, and then quench with 2.4 ml of 2M glycine. Centrifuge for 15 minutes at 1,200 rpm at 4°C, and remove the supernatant. Wash the pellet once with 40 ml ice cold PBS, then spin down the pellet and remove the PBS.

2. Cell lysis to isolate nuclei

1. Resuspend cells in 40 ml of ice cold lysis buffer (10 mM Tris-HCl, pH8.0, 10 mM NaCl, 0.2% NP-40) with freshly added protease inhibitors (1:500 dilution) and 0.1 mM PMSF. Incubate in a cold room with rotation for 90 minutes, centrifuge at 2,500 rpm for 15 minutes, and remove the supernatant.

3. Restriction enzyme digestion with Bgl II

1. Resuspend the nuclei in 0.5 ml of 1 x NEB buffer 3, and add 15 μlof 10% SDS. Incubate at 37°C for 1 hour with shaking, then add 45 μl of 20% Triton X-100 to sequester the SDS. Incubate at 37°C for 1 hour with shaking.
2. Use an aliquot of 1 x 10⁶ nuclei (about 15 μg, one tenth of the original cells) for restriction enzyme digestion. Take out 55 μl of nuclei solution from Step 3.1 and make up to 500 μl with 433 μl of 1 x NEB buffer 3 and 12 μl of Bgl II(50U/ul). Incubate at 37°C overnight.

4. Ligation of interacting DNA segments

1. Inactivate the restriction enzyme by adding 95 μl of 10% SDS, and denature by heating at 65 °C for 20 minutes in a water bath.
2. Add 7 ml of 1 x ligation buffer (30 mM Tris-HCl, pH 8.0, 10 mM MgCl₂, 10 mM DTT, 1 mM ATP) and 360 μl of 20% Triton X-100 and incubate at 37°C for 1 hour.
3. Lower the temperature to 16°C and add 50 μl of 400 U/μl T4 DNA ligase. Incubate the sample at 16 °C for 4 hours and then at room temperature for 30 minutes.

5. DNA Purification

1. Add 300 μg of proteinase K, and incubate at 65°C overnight.
2. Add 5 μg of RNase A and incubate at 37°C for 30 minutes
3. Purify DNA by phenol/chloroform extraction, and precipitate DNA in isopropanol. Dissolve DNA in 150 μl of sterile distilled water.

6. Digestion with Msp I and ligation with oligonucleotide linkers

1. Incubate 2μg of purified DNA with 5 units of Msp I at 37°C for 4-6 hours. Inactivate Msp I at 65°C for 10 minutes, then precipitate the DNA in ethanol with 1 μl of 5 mg/ml glycogen. Dissolve the DNA pellet in 50 μl of sterile distilled water.
2. Mix 50 μl of Msp I-treated DNA with 2 μl of a 20 μM linker oligonucleotide L (5'-gctgaccctgaattcgcacgtgcctgtcgttagcggacacagggcgattcac-3'), 1 μl of a 20 μM oligonucleotide S (5'-cggtgaatc-3'), 1 μl of sterile distilled water and 6 μl of 10 x T4 DNA ligase buffer. Cover the mixture with liquid wax.
3. Denature oligonucleotides at 50°C for 1 minute and allow to cool down gradually to 10°C in a 0.5°C /minute gradient in a thermal cycler.
4. Add 1 μl of 400 U/μl T4 DNA ligase and incubate at 15°C overnight. Purify the linker-ligated DNA using a QIAquick PCR Purification kit, and elute in 50 μl of sterile distilled water.

7. PCR amplification and sequence analysis

1. Choose a primer for the specific region of DNA that you wish to examine for long-range interactions (i.e., the 'bait'). In this example, we use ABL-1.
2. Take 1 μl of the purified DNA to perform the first round PCR using 1 μl of 20 μM ABL-1 specific primer #4656 (5'-gttcaagcgattctcctgcctcga-3'), 1 μl of 20 μM linker specific primer #2963 (5'-gctgaccctgaattcgcacgtgcct-3'), 3μl of 3 x Klen Taq DNA polymerase I cocktail and 3 μl of sterile distilled water. Two μl of ³²P-dCTP is added to 100 μl of 3 x Klen Taq DNA polymerase I cocktail before PCR amplification. The thermal cycle for a hot start PCR is 72°C for 2 min, 95° Cfor 2 minutes; 18 cycles of 95°C for 20 seconds, 65°C for 40 seconds, and 72°C for 1 minute; the final extension is performed at 72°C for 5 minutes.
3. Purify the first round PCR products using a QIAquick PCR Purification kit, and elute DNA in 30 μl of sterile distilled water.
4. Take 1 μl of 100 x diluted first PCR product to perform a second round of PCR using nested primers by adding 1 μl of 20 μM ABL-1 specific primer #4626 (5'-ggagaatttttatctgcctctgtga-3') (Figure 1a),1 μl of 20 μM of linker specific primer #2961 (5'-gtcgttagcggacacagggcgattc-3'), 3 μl of 3 x Klen Taq DNA polymerase I cocktail and 3 μl of sterile distilled water. The thermal cycling schedule is 25 cycles of 95°C for 20 seconds, 67°C for 40 seconds, and 72°C for 1 minute, followed by extension at 72°C for 5 minutes.
5. Visualize the PCR products by running a 5% urea-PAGE gel and scanning the exposed screen in a PhosphoImager (Figure 1b). Each PCR band can be recycled from the gel by dissolving the gel strips in an Eppendorf tube containing 60 μl of sterile distilled water, and incubating at 95°C for 5 minutes. Centrifuge briefly at 10,000 rpm for 10 sec to collect all the samples. Remove 1 μl to use as the DNA template to perform PCR with the primer pair 2961/4626 using the same conditions as described above. Sequence analysis can be performed after purification using a QIAquick PCR Purification kit.
6. DNA sequences are analyzed using an online tool to determine their chromosomal location at the web site:http://genome.ucsc.edu(Figure 1c). Click 'BLAT' to enter a new window which allows to paste a DNA sequence, a new window appears after clicking 'submit', and shows the 'BLAT Search Results'. Click 'browser' of the hit with 100% identity to enter a next window to show the location of the DNA sequence.

8. Representative Results

1. ACT assay using ABL-1 region as bait to determine its long range DNA interactions

As illustrated in Figure 1a, two Bgl II sites and one BamH I site were chosen for the ACT assay. In the second round of PCR, primer set 4626/2961 was used to amplify ABL-M1, 4630/2961 was used for ABL-M2, and 4636/2961 was used for ABL-M3. A typical gel pattern shows one to several bands (Figure 1b). Each fragment from an ACT assay consists of two combined DNA segments: one segment is derived from the bait DNA region, while the second segment comes from the associated partner, which was joined to the bait region segment by the first restriction enzyme recognition sequence. The second enzyme recognition sequence will appear at the end of the associated partner sequence (Figure 1c). The cloned ABL-M1 fragment contains DNA from the region of ABL1 located at chromosome 9q32.4 from +133,592,306-133,592,399, and the associated partner is located at chromosome 3p13 from +71,869,882-71,870,107. The identities of the associated partners are discovered by blasting their sequences using the UCSC genome browser (GRCh7/hg19 released in February, 2009). PROK2 was identified as the associated partner at the chr3p13 locus.

Similarly, the ABL-M2 associated partner was localized to chr5q21.1, while clone ABL-M3 was identified as an intra-chromosomal association near the ABL-1 locus.

2. Determining less prevalent long range interactions using ACT assay

Other assays based on 3C have reported many more interacting partners than that we have shown in Figure 1 and at the Igf2/H19 locus¹². The methodology that we have outlined will select the most prevalent long range interactions. However, by increasing the number of PCR cycles, it is possible to identify additional, less frequent associations as well (Figure 2).

3. Differences in long range interactions in cancer cells when compared to normal tissues.

The ACT assay can also be used to identify differences in nuclear architecture and long range interactions between normal cells and cancer cells (Figure 3). These differences may reflect nuclear architecture changes that occur during cell transformation, and thus this assay may ultimately be applicable for diagnostic purposes. The similar gel patterns that occur in both normal and cancer tissues indicated that the ACT assay is reliable and repeatable. While the ACT assay can identify long range DNA partners, further analyses, such as FISH and ChIP assays, are required to verify the presence of the identified associations between distant loci. Genetic, physiological and biochemical studies can then be performed to elucidate the biological implications of these long range DNA associations.

Figure 1 ACT assay using ABL-1 region as bait DNA in HL-60 cells. a. DNA structure in ABL-1 region. The first restriction enzyme used in ACT assay was Bgl II. The primers for the second round of PCR are also labeled by arrows and corresponding primer numbers. b. Gel pattern of the ACT assay in 5% urea-PAGE. Primer pair 4626/2961 was used for amplifying clone ABL-M1 in the nested PCR, 4630/2961 was used for clone ABL-M2, and 4636/2961 was used for clone ABL-M3. c. DNA sequence of clone ABL-M1. DNA fragment from ABL-1 bait DNA is labeled in red, and the associated DNA partner is labeled in cyan. Bgl II site (AGACTC) was labeled in green, and Msp I site (CCGG) is labeled in purple.

Figure 2 PCR cycles affect ACT assay results. Using the imprinting control region (ICR) at the Igf2/H19 locus as bait DNA in mouse fibroblast cells, different cycling programs were applied in the first and second rounds of PCR in the ACT assay. 18-20 cycles in the first round of PCR did not amplify enough signal to be visualized. Twenty five cycles in the second PCR results in clear bands, while increasing the number of cycles for the second round of PCR induced a smear pattern in addition to more bands.

Figure 3 Detection of differences in nuclear architecture between normal colon tissue and colon cancer tissue in ACT assay. a. DNA structure of the ICR region at IGF2/H19 locus and IGF2 gene. Dpn II sites for ACT assay are labeled. Primers used in the second round PCR are labeled by arrows and numbers in different colors which correspond to each lane in panel b of the figure. b. Gel pattern of the ACT assay in 5% urea-PAGE. Normal colon tissue MAD03-1423 and colon cancer tissue MAD04-149 was obtained from Cooperative Human Tissue Network (CHTN) Western Division. After each colon tissue was homogenized, ACT assay was performed following the procedures described herein. Lane 1 represents the PCR results using primer pair #2961and #4161(5'-tctgcgccatcagggcagtgagac-3') labeled in pink in panel a; lane 2 represents the PCR results using primer pair #2961 and #4163 (5'-gccgcgcggccacttccgattcc-3') labeled in orange in panel a; lane 3 represents the PCR results using primer pair #2961 and #5145 (5'-gccatgcaggtaggatttgagctg-3') labeled in blue in panel a; lane 4 represents the PCR results using primer pair #2961 and #5151(5'-gtctcaaataggggccagctagcttgg-3') labeled in green in panel a. Unique bands that appear only in normal colon tissue are labeled by yellow arrows, and those bands that appeared only in colon cancer tissue are labeled in red arrows. ICR, imprinting control region; DMR, different methylated region.

Discussion

Dekker et al. developed the chromosome conformation capture (3C) approach to detect the frequency of interaction between two genomic loci¹, and 3C has been used extensively to investigate intra-chromosomal and inter-chromosomal associations between two known DNA regions in mammalian cells^2-9. Although newly developed Hi-C methodology can be applied for study of genome-wide DNA association, ACT assay is still an effective technique for study of locus-specific DNA interaction^10-11. We have modified this approach to identify unknown DNA regions that are associated with a known DNA region in cultured mouse and human cells (Figure 1). We named this method the associated chromosome trap (ACT) assay, as it provided us a reliable and reproducible method to identify novel unknown DNA partners that associate with a known target DNA region¹². A successful 3C assay with appropriate controls is performed before executing the novel aspects of the ACT assay¹³. In order tofind as many associated DNA regions as possible, it is necessary to use various combinations of first and second restriction enzymes. It is especially important to use restriction enzymes that are insensitive to CpG methylation to perform the first 3C ligation step. Protein binding and DNA methylation can also influence restriction enzyme digestion efficiency and can lead to failure of ligation of the associated DNA regions for certain restriction enzyme digestions. The occurrence of intra- or inter-chromosomal ligation depends on protein-DNA cross-linking and appropriate physical maps of both of the associated DNA regions. Thus, some preliminary experiments are essential to establish a practicable effective formaldehyde concentration and treatment time in the ACT assay. A range of final concentrations of formaldehyde (from1.5% to 2%) have been used in several labs during the 3C portion of the assay^7,9. Alternatively, the oligonucleotides used as linkers can be designed to match the cohesive end cut by the second restriction enzyme. Although we found that 18-20 cycles in the first round of PCR and 20-25 cycles in the second round of PCR could provide clear bands, it is necessary to establish the best PCR conditions for each experiment (Figure 2).Intra-molecule annealing between 5'-end and 3'-end complementary adaptor sequence of a DNA strand may occur in PCR, it inhibits adaptor-specific primer annealing with the DNA molecule, and resulted in much lower amplification efficiency in the first several cycles. After the target DNA was amplified for cycles, its amount may be much larger than these nonspecific reactions, and may facilitate the competition of primer annealing to the target DNA molecules. This is also why we may see background amplification, and why the first round PCR product has to be diluted to decrease background amplification.It is important to remove excess primers from the PCR reaction in order to decrease the background in the second round of PCR. As in all PCR-based experiments, it is vital to design primers that are not located in repeat sequence regions, which constitute the majority of human and mouse DNA. Although newly developed Hi-C methodology can be applied for study of genome-wide DNA association, ACT assay is still an effective technique for study of locus-specific DNA interaction.

Materials

Name	Company	Catalog Number	Comments
RPMI1640 medium	Invitrogen	22400-105
acrylamide	Invitrogen	15512-023
ATP solution, 10mM	Invitrogen	AM8110G
fetal bovine serum	Invitrogen	16000-044
penicillin-streptomycin	Invitrogen	15140-122
1M Tris pH8.0	Invitrogen	AM9856
RNase A	Invitrogen	12091-039
SDS	Invitrogen	15525-017
urea	Invitrogen	15505-035
BamH I	New England Biolabs	R0136T
Bgl II	New England Biolabs	R0144M
Dpn II	New England Biolabs	R0543T
Msp I	New England Biolabs	R0106S
dNTPs	New England Biolabs	N0447L
proteinase K	New England Biolabs	P8102S
T4 DNA ligase	New England Biolabs	M0202T
37% formaldehyde	Sigma-Aldrich	F8775
Bis-acrylamide	Sigma-Aldrich	146072
dithiothreitol	Sigma-Aldrich	43815
glycine	Sigma-Aldrich	50046
PMSF	Sigma-Aldrich	93482
proteinase inhibitor	Sigma-Aldrich	S8830
Nonidet P-40	Roche Group	11754599001
KlenTaq1	Ab peptides	1001
dCTP alpha P32	PerkinElmer, Inc.	BLU513H250UC
PTC-100 Thermal Cycler	MJ Research	mjptc100
Power Supply	Bio-Rad	164-5056
OmniPAGE Maxi	Aurogene Life Science	VS20D
Typhoon 9400	GE Healthcare	63-0055-78